ReviewClinical epigenetics2025
Epigenetic regulatory mechanisms of autoimmune skin diseases: novel biomarkers and therapeutic prospects.
Review in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Protein Post-Translational Modifications in UV-Induced Skin Damage.Experimental dermatology · 2026Review
- Molecular Pathogenesis of Vitiligo: Emerging Roles of Epigenetic Regulation.Biomolecules & therapeutics · 2026Review
- From Genes to Pathways: The Molecular Landscape of Systemic Lupus Erythematosus.International journal of molecular sciences · 2026Review
- Cutaneous Manifestations of Inborn Errors of Immunity: Clinical Clues to Immune Disorders.Medicina (Kaunas, Lithuania) · 2026Review
- Epigenetic Therapies for Inflammatory and Immune-Mediated Skin Diseases.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Autoimmune skin diseases (AISDs) are disorders characterized by disrupted immune tolerance and aberrant responses against skin antigens, including atopic dermatitis (AD), psoriasis, systemic lupus erythematosus (SLE), bullous pemphigoid (BP), and other common conditions. Dysregulated expression of immune-related genes-particularly those governing B and T cell functions-holds promise as diagnostic and prognostic biomarkers, though their regulatory mechanisms remain incompletely defined. This review systematically synthesizes recent evidence elucidating the central role of three core epigenetic mechanisms-DNA methylation, histone modifications (including emerging metabolically linked alterations), and noncoding RNAs (ncRNAs)-in driving AISD pathogenesis. We highlight the dynamic interplay between epigenetic dysregulation, immune dysfunction, and skin barrier impairment. Deciphering these epigenetic networks and identifying key regulators (e.g., DNMTs, histone-modifying enzymes, ncRNAs) may enable high-precision diagnostics and novel therapies to restore immune homeostasis. Such advances will deepen mechanistic insights and transform clinical management paradigms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.